News

BerGenBio to Present Company Update at DNB Nordic Healthcare Conference

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Third Quarter Results 2024

BerGenBio ASA: Invitation to third quarter 2024 results webcast

CEO Martin Olin steps down

BerGenBio ASA: Minutes from Extraordinary General Meeting

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference